Primary sclerosing cholangitis: epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and management

Primary sclerosing cholangitis (PSC) is a rare cholangiopathy characterized by multifocal inflammation and fibrostenotic remodeling of the bile ducts, cholestasis, and increased risks of cholangiocarcinoma and colorectal cancer. No pharmacological therapy has yet improved transplant-free survival. Clinical care therefore depends on accurate phenotyping, surveillance, treatment of biliary and intestinal complications, and timely liver transplantation. Population-based and clinical studies define the epidemiology, risk factors, presentation, diagnosis, and management of PSC. Studies of human biospecimens, including microbiome and metabolomic analyses, describe biological changes associated with the disease, whereas organoid and animal models are used to investigate potential mechanisms. The available evidence links genetic susceptibility and PSC-associated inflammatory bowel disease to cholangiocyte injury, immune activation, disturbed bile acid homeostasis, and microbial alterations. At the bile duct interface, cholangiocyte senescence and barrier dysfunction may interact with microbial exposure and immune-cell recruitment to promote periductal fibrosis. PSC is therefore more plausibly viewed as a multicellular process than as the consequence of a single microbial, immune, or bile acid pathway. Whether dysbiosis and altered bile acid profiles contribute to disease development or instead reflect established PSC remains unresolved. Concomitant inflammatory bowel disease, medication use, biliary obstruction, and previous biliary interventions further complicate causal inference. Longitudinal human studies may distinguish early drivers from secondary changes. Mechanistic findings should ultimately improve patient phenotyping, surveillance, endoscopic management, and selection for targeted trials. Such trials will require biologically informed designs and endpoints that capture durable clinical benefit.

Authors

Institutions

Publication Details

Journal
Molecular Biomedicine
Published
2026-11-21
DOI
https://doi.org/10.1186/s43556-026-00662-7
Primary Topic
Liver Diseases and Immunity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Primary sclerosing cholangitis: epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and management

Qiang Xia, Yuan Liu, Zhicong Zhao, Bingran Wang et al.
Molecular Biomedicine
Liver Diseases and Immunity
article

Primary sclerosing cholangitis: epidemiology, risk factors, pathophysiology, clinical features, diagnosis, and management

Qiang Xia, Yuan Liu, Zhicong Zhao, Bingran Wang, Taihua Yang, Jiaqi Song, Yuan Liu, Xiong Ma
article en

Abstract

Primary sclerosing cholangitis (PSC) is a rare cholangiopathy characterized by multifocal inflammation and fibrostenotic remodeling of the bile ducts, cholestasis, and increased risks of cholangiocarcinoma and colorectal cancer. No pharmacological therapy has yet improved transplant-free survival. Clinical care therefore depends on accurate phenotyping, surveillance, treatment of biliary and intestinal complications, and timely liver transplantation. Population-based and clinical studies define the epidemiology, risk factors, presentation, diagnosis, and management of PSC. Studies of human biospecimens, including microbiome and metabolomic analyses, describe biological changes associated with the disease, whereas organoid and animal models are used to investigate potential mechanisms. The available evidence links genetic susceptibility and PSC-associated inflammatory bowel disease to cholangiocyte injury, immune activation, disturbed bile acid homeostasis, and microbial alterations. At the bile duct interface, cholangiocyte senescence and barrier dysfunction may interact with microbial exposure and immune-cell recruitment to promote periductal fibrosis. PSC is therefore more plausibly viewed as a multicellular process than as the consequence of a single microbial, immune, or bile acid pathway. Whether dysbiosis and altered bile acid profiles contribute to disease development or instead reflect established PSC remains unresolved. Concomitant inflammatory bowel disease, medication use, biliary obstruction, and previous biliary interventions further complicate causal inference. Longitudinal human studies may distinguish early drivers from secondary changes. Mechanistic findings should ultimately improve patient phenotyping, surveillance, endoscopic management, and selection for targeted trials. Such trials will require biologically informed designs and endpoints that capture durable clinical benefit.

Molecular BiomedicineVol. 7(1)
Shanghai Jiao Tong University (CN), Renji Hospital (CN)
Liver Diseases and Immunity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon